Salute e Benessere

141,959 Orion Corporation A shares converted into B shares

ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE23 June 2025 at 9.30 EEST 141,959 Orion Corporation A shares converted into B shares In accordance with Section 3 of the Articles of Association of Orion Corporation, 141,959 A shares have been converted into 141,959 B shares. The conversion has been entered into the Trade Register on 23 June 2025.The total number of shares in Orion Corporation is 141,134,278 which,...
Nasdaq GlobeNewswire
23/06/2025

Navamedic ASA expands into addiction treatment through the acquisition of the…

The Acquisition The Acquisition The Acquisition encompassesdne pharma'sbusiness, including product portfolio, key employees and all essential contracts of the business, intellectual property, licenses, and distribution agreements. The product portfolio includes prominent products such as Ventizolve® (intranasal naloxone spray for opioid overdose reversal), Levopidon® (levomethadone), and Metadon Dne (methadone) for opioid substitution therapy. The Acquisition (i) marks Navamedic's...
PR Newswire
23/06/2025

AB Science - New peer-reviewed data provide strong evidence supporting masitinib…

PRESS RELEASENEW PEER-REVIEWED DATA PROVIDE STRONG EVIDENCE SUPPORTING MASITINIB’S POTENTIAL FOR THE TREATMENT OF ALZHEIMER’S DISEASE THROUGH A DUAL MECHANISM OF COGNITIVE ENHANCEMENT AND NEUROPROTECTIONTHIS PUBLICATION CORROBORATES NEW ANALYSIS FROM THE CLINICAL PHASE 2B/3 STUDY SHOWING COGNITIVE IMPROVEMENT UNDER MASITINIB TREATMENT PHASE 3 CLINICAL STUDY WITH MASITINIB AS A DISEASE-MODIFYING THERAPY FOR ALZHEIMER’S DISEASE HAS BEEN AUTHORIZED BY THE FDA AND KEY EU COUNTRIES...
Nasdaq GlobeNewswire
23/06/2025

Galapagos Appoints Aaron Cox as Chief Financial Officer

Former Horizon CFO joins Galapagos with deep expertise in international corporate finance, M&A, business development and strategic leadership Mechelen, Belgium; June 23, 2025, 07:30 CET; regulated information – inside information – Galapagos NV (Euronext & NASDAQ: GLPG) today announced the appointment of Mr. Aaron Cox as Chief Financial Officer, effective July 7, 2025. Mr. Cox succeeds Mr. Thad Huston, who will remain with the company through July 31, 2025, to ensure a smooth...
Nasdaq GlobeNewswire
23/06/2025

Idorsia’s QUVIVIQ expands into China as Simcere receives NDA approval – Idorsia…

Ad hoc announcement pursuant to Art. 53 LR Idorsia to receive USD 50 million (an additional USD 30 million) approval milestone payment in return for a reduction in Simcere potential sales milestones and tiered royalty payments.Allschwil, Switzerland – June 23, 2025Idorsia Ltd. (SIX: IDIA) today announced that Simcere Pharmaceuticals Group Ltd (2096.HK, “Simcere”) has received approval for QUVIVIQ ®(daridorexant) from the Chinese National Medical Products Administration for the...
Nasdaq GlobeNewswire
23/06/2025

Press Release: Sarclisa recommended for EU approval by the CHMP to treat…

Sarclisa recommended for EU approval by the CHMP to treat transplant-eligible newly diagnosed multiple myelomaRecommendation based on GMMG-HD7 phase 3 study demonstrating that Sarclisa with VRd induction treatment significantly improved MRD negativity benefit and prolonged PFS compared to VRd aloneIf approved, it would represent the fourth indication in the EU and second in the front-line setting globallyParis, June 23, 2025.The European Medicines Agency’s Committee for...
Nasdaq GlobeNewswire
23/06/2025

Early data suggest Roche’s NXT007 may have the potential to provide haemostatic…

Positive phase I/II data presented at the 2025 International Society on Thrombosis and Haemostasis (ISTH) Congress show NXT007 achieved no bleeds requiring treatment in the highest dose groups in people with haemophilia A 1 The NXT007 clinical development programme aims to normalise haemostasis and minimise treatment burden 2,3 Three phase III clinical studies on NXT007, a next-generation bispecific antibody, set to begin in 2026 1Basel, 23 June 2025 - Roche (SIX: RO,...
Nasdaq GlobeNewswire
23/06/2025

Novartis announces expiration of HSR waiting period of Regulus Therapeutics…

Basel, June 23, 2025– Novartis today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), in connection with Novartis’ previously announced tender offer to acquire all of the outstanding shares of common stock, par value $0.001 per share (the “Shares”), of Regulus Therapeutics Inc. (“Regulus”), in exchange for (i) $7.00 in cash per Share, subject to any applicable withholding and without interest thereon,...
Nasdaq GlobeNewswire
23/06/2025

EAN Congress: Frequent nightmares triple risk of early death and accelerate…

Nightmare frequency in adults was self-reported at the start of the study, with participants followed for up to 19 years. For children, nightmare frequency was reported by their parents at the beginning of the study. Nightmare frequency in adults was self-reported at the start of the study, with participants followed for up to 19 years. For children, nightmare frequency was reported by their parents at the beginning of the study. Results showed that adults reporting weekly nightmares were...
PR Newswire
23/06/2025

Novo Nordisk A/S: Mim8 prophylaxis treatment shown to be well-tolerated when…

New FRONTIER5 data show that a direct switch to investigational Mim8 (denecimig) prophylaxis treatment from emicizumab, without the need for a washout period, was well-tolerated with no safety concerns in adults and adolescents with haemophilia A, with or without inhibitors 1.Switching to Mim8 led to a sustained increase in thrombin generation into the normal range, but without causing thrombin levels that might pose a thrombotic risk 1.FRONTIER5 Patient-Reported Outcomes (PROs)...
Nasdaq GlobeNewswire
22/06/2025

Novo Nordisk A/S: CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight…

Data presented simultaneously at the American Diabetes Association’s ®85 thScientific Sessions, showed mean weight reduction in the highest range of efficacy observed with existing weight loss interventions 1 When adhering to treatment, weight loss of ≥5%, ≥20%, ≥25%, and ≥30% was observed in 97.6%, 60.2%, 40.4% and 23.1% of patients respectively at 68 weeks 1* The REDEFINE clinical programme is ongoing to further investigate efficacy and safety of CagriSema, including recently...
Nasdaq GlobeNewswire
22/06/2025

Gan & Lee Pharmaceuticals Presented Multiple Results in Novel Diabetes Therapies…

In this Phase 2a clinical trial (NCT06256523), 36 adults with T2DM who had inadequate glycemic control through diet and exercise and/or irregular use of antidiabetic medications, were randomized to receive either bofanglutide injection (N=27) or placebo (N=9) once weekly (QW) for 23 weeks, with a dose escalating from 1.5 mg to 13 mg. The key efficacy endpoint was HbA1c change from baseline to week 23. In this Phase 2a clinical trial (NCT06256523), 36 adults with T2DM who had inadequate…
PR Newswire
21/06/2025

New data demonstrates robust efficacy of Vyepti® (eptinezumab) in otherwise…

"Patient education is often employed as a therapeutic strategy for patients with chronic migraine and medication-overuse headache, while preventive anti-CGRP treatments are reserved for later stages," said Dr. Rigmor Højland Jensen, Associate Professor at University of Copenhagen, Director of the Danish Headache Center, and lead investigator on the RESOLUTION trial. "The RESOLUTION trial demonstrates for the first time, that adding an anti-CGRP treatment early, and alongside…
PR Newswire
21/06/2025

New data from phase III trial confirms efficacy of Vyepti® (eptinezumab) in…

The double-blind, pivotal, SUNRISE trial (n=983) met all key primary and secondary endpoints, with eptinezumab demonstrating greater reductions in migraine frequency, the proportion of migraine attacks with severe pain, and disease burden, compared to placebo.1 The double-blind, pivotal,SUNRISEtrial (n=983) met all key primary and secondary endpoints, with eptinezumab demonstrating greater reductions in migraine frequency, the proportion of migraine attacks with severe pain, and disease...
PR Newswire
21/06/2025

Changsha uses engineering expertise to engage in BRI

Enterprises in this field from the Xiangjiang New Area in Changsha have carried out important cooperation projects in Saudi Arabia, contributing Hunan's strength to build an Arab-China community with a shared future and promoting the high-quality development of the BRI. Enterprises in this field from the Xiangjiang New Area inChangshahave carried out important cooperation projects inSaudi Arabia, contributingHunan'sstrength to build an Arab-China community with a shared future and...
PR Newswire
21/06/2025

Novo Nordisk: Higher dose of Wegovy® provided average weight loss of 21% in…

Higher dose of Wegovy ®provided average weight loss of 21% in people with obesity – with a third achieving 25% or more – according to data presented at ADAResults from the phase 3b STEP UP trial showed that a higher dose of Wegovy ®(semaglutide 7.2 mg) delivered 21% weight loss in people with obesity, with a third of participants losing 25% or more of their weight, compared to placebo 1 Safety and tolerability of the higher dose of Wegovy ®(semaglutide 7.2 mg) was consistent...
Nasdaq GlobeNewswire
21/06/2025

Novo Nordisk’s subcutaneous and oral amycretin data published in The Lancet and…

Subcutaneous amycretin phase 1b/2a data on the safety, tolerability and weight loss potential in people with overweight or obesity was published in The Lancet and presented at the American Diabetes Association (ADA) Scientific Sessions. 1,2 Oral amycretin phase 1 data on the safety, tolerability and weight loss potential in people with overweight or obesity was also published in The Lancet. 3 Findings from the clinical trials indicate amycretin appeared tolerable with a safety...
Nasdaq GlobeNewswire
21/06/2025

Innocan Pharma Announces Presentation of Narrative Review on Long-Acting…

Innocan is developing LPT-CBD, an innovative injectable liposomal drug product designed for the sustained release of synthetic CBD. Supported by multiple animal studies, LPT-CBD has demonstrated steady plasma CBD levels for up to four weeks, prolonged pain relief, and excellent tolerability—offering a promising alternative to current opioid medications and addressing the urgent need to reduce opioid dependency. Innocan is developing LPT-CBD, an innovative injectable liposomal drug product...
PR Newswire
20/06/2025

OSE Immunotherapeutics Reaffirms Commitment to Holding a Transparent and Serene…

OSE Immunotherapeutics Reaffirms Commitment to Holding a Transparent and Serene General Meeting in Compliance with Market Rules Nantes, June 20 th, 2025, 7:30 p.m.-OSE Immunotherapeutics SA( ISIN: FR0012127173; Mnemo: OSE),publishes a “Questions and Answers” document for all its shareholders and informs the market of ongoing procedures, in line with its commitment to holding the annual General Meeting with transparency, serene debates, and compliance with market rules...
Nasdaq GlobeNewswire
20/06/2025

Casino Group: Information regarding buy-out of minority shareholders of Cnova…

Information regarding buy-out of minority shareholdersof Cnova N.V. – Implementation of squeeze-out Paris, France / Amsterdam, the Netherlands, 20 June 2025 Reference is made to Casino’s press release regarding the Mandatory Buy-Out of the Cnova shares, (i) dated 17 October 2024, (ii) dated 12 February 2025, (iii) dated 31 March 2025 and (iv) dated 16 June 2025. Casino, Guichard-Perrachon S.A. (Euronext Paris: CO; ISIN: FR001400OKR3) (“ Casino ”) hereby announces the following:...
Nasdaq GlobeNewswire
20/06/2025

Grupo Dia strengthens its Board of Directors to support Strategic Plan 2025-29

Alberto Gavazzi assumes the presidency of the Board in the new phase of accelerated growth of Dia Dia’s pivot to a sustainable growth agenda. Babcock will continue as a proprietary director and principal representative of LetterOne, Grupo Dia’s reference shareholder.The General Shareholders’ Meeting also approved the appointment ofRut Aranda, Sara Díez JaureguiandPaloma Pérezas independent directors. These appointments add the talent of three professionals with proven track...
Nasdaq GlobeNewswire
20/06/2025

Roche’s Lunsumio and Polivy combination significantly prolongs remission for…

Pivotal phase III SUNMO study demonstrated an 11.5 month median progression-free survival - three times longer than R-GemOx 1 This well-tolerated investigational combination therapy avoids traditional chemotherapy and may be suitable for outpatient community careThese data demonstrate Roche's commitment to providing options for diverse patient and healthcare system needs in this difficult-to-treat lymphomaBasel, 20 June 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) presented today...
Nasdaq GlobeNewswire
20/06/2025

Medical Imaging Equipment Market Size to Hit USD 62.51 Billion by 2031 with 4.5%…

To explore the valuable insights in the Medical Imaging Equipment Market report, you can easily download a sample PDF of the report - https://www.businessmarketinsights.com/sample/BMIPUB00031626/ To explore the valuable insights in the Medical Imaging Equipment Market report, you can easily download a sample PDF of the report -https://www.businessmarketinsights.com/sample/BMIPUB00031626/ Technology is starting to become a major driver for this market. We expect integrated capabilities...
PR Newswire
20/06/2025

2024 Cell and Gene Therapy Market Set for Breakthrough Growth, Says BCC Research

Key Highlights: • Cell and Gene Therapy Tools, and Reagents: Global Markets: • Cell Therapy Biomanufacturing: Global Markets: • Gene Synthesis: Technologies and Global Markets: Research Coverage and Insights:This Research Review provides a clear snapshot of the fast-moving cell and gene therapy (CGT) industry. It looks at how these technologies are being used across the entire development pipeline from early research to clinical use and large-scale...
PR Newswire
20/06/2025
Altri  Comunicati